Beliefs About Medication and Uptake of Preventive Therapy in Women at Increased Risk of Breast Cancer: Results From a Multicenter Prospective Study

[1]  R. Horne,et al.  Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews , 2018, Breast Cancer Research and Treatment.

[2]  A. Walker,et al.  Impact of NICE guidance on tamoxifen prescribing in England 2011–2017: an interrupted time series analysis , 2018, British Journal of Cancer.

[3]  K. Payne,et al.  Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients’ Medication Beliefs and Habit Strength , 2017, The Journal of investigative dermatology.

[4]  J. Cuzick,et al.  Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  S. Smith,et al.  Decision-making in breast cancer prevention: The ENGAGE study , 2017 .

[6]  J. Cuzick,et al.  Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I) , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  W. Rief,et al.  Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  J. Costantino,et al.  Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1. , 2016, Journal of the National Cancer Institute.

[9]  J. Wardle,et al.  Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Cuzick,et al.  Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial , 2015, The Lancet. Oncology.

[11]  J. Cuzick,et al.  Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic , 2014, British Journal of Cancer.

[12]  N. Freemantle,et al.  Understanding Patients’ Adherence-Related Beliefs about Medicines Prescribed for Long-Term Conditions: A Meta-Analytic Review of the Necessity-Concerns Framework , 2013, PloS one.

[13]  A. LaCroix,et al.  Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data , 2013, The Lancet.

[14]  Communities,et al.  English Indices of Deprivation , 2013 .

[15]  R. Horne,et al.  The perceived sensitivity to medicines (PSM) scale: an evaluation of validity and reliability. , 2013, British journal of health psychology.

[16]  E. Leventhal,et al.  Physicians' communication of the common-sense self-regulation model results in greater reported adherence than physicians' use of interpersonal skills. , 2012, British journal of health psychology.

[17]  M. Regan,et al.  Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[19]  J. Weinman,et al.  The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication , 1999 .